Novel transcript, antisense to SLC22A16 (ENSG00000260188)

The entry "novel transcript, antisense to SLC22A16" refers to a non-coding RNA transcript oriented antisense (opposite DNA strand direction) to the SLC22A16 gene on the human genome. Antisense transcripts are commonly identified in genome-wide transcriptome annotations and typically do not code for proteins or act as direct therapeutic targets. Instead, they may regulate expression of the sense gene through mechanisms affecting chromatin structure, transcription, or RNA stability, as shown in studies of antisense transcription more generally. There is no evidence that this specific transcript is a validated therapeutic target or has a defined biological or disease role. It is not a receptor, transporter, enzyme, or standard drug target, but an example of a non-coding regulatory element. The SLC22A16 gene encodes a protein involved in carnitine and drug transport and is itself a therapeutic target in some cancers. The antisense transcript, however, is not the same entity. Antisense RNAs can modulate the sense transcript (e.g., SLC22A16) by altering chromatin and transcription dynamics, but these effects are general phenomena and not specific to this entry. "Novel transcript, antisense to SLC22A16" is listed in genome databases as a transcript locus only, not a protein or validated target. This entry does not correspond to a standard molecular target (such as a receptor, enzyme, or transporter) and should not be classified as a "target" in a therapeutic or drug discovery sense. There is no evidence of disease roles, biomarkers, or safety concerns associated with this specific antisense RNA. If you are seeking data about the SLC22A16 protein (a bona fide transporter and drug target), refer instead to "Solute carrier family 22 member 16".

Other names

novel antisense transcript to SLC22A16

Not applicable; no drugs known to interact with this non-coding RNA